JP2019518084A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019518084A5 JP2019518084A5 JP2019518350A JP2019518350A JP2019518084A5 JP 2019518084 A5 JP2019518084 A5 JP 2019518084A5 JP 2019518350 A JP2019518350 A JP 2019518350A JP 2019518350 A JP2019518350 A JP 2019518350A JP 2019518084 A5 JP2019518084 A5 JP 2019518084A5
- Authority
- JP
- Japan
- Prior art keywords
- topical formulation
- histidine
- formulation according
- skin
- nucleophile
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000012049 topical pharmaceutical composition Substances 0.000 claims 18
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims 10
- 210000003491 Skin Anatomy 0.000 claims 5
- 208000003251 Pruritus Diseases 0.000 claims 4
- 239000012038 nucleophile Substances 0.000 claims 4
- XSQUKJJJFZCRTK-UHFFFAOYSA-N urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims 4
- DQAKJEWZWDQURW-UHFFFAOYSA-N 2-oxopyrrolidine-1-carboxylic acid Chemical class OC(=O)N1CCCC1=O DQAKJEWZWDQURW-UHFFFAOYSA-N 0.000 claims 3
- 235000001014 amino acid Nutrition 0.000 claims 3
- 150000001413 amino acids Chemical class 0.000 claims 3
- 201000004624 dermatitis Diseases 0.000 claims 3
- 231100000406 dermatitis Toxicity 0.000 claims 3
- 230000002265 prevention Effects 0.000 claims 3
- 206010013786 Dry skin Diseases 0.000 claims 2
- 229940079889 Pyrrolidonecarboxylic Acid Drugs 0.000 claims 2
- 239000004202 carbamide Substances 0.000 claims 2
- 230000037336 dry skin Effects 0.000 claims 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims 2
- 239000004475 Arginine Substances 0.000 claims 1
- 102100000354 FLG Human genes 0.000 claims 1
- 206010021639 Incontinence Diseases 0.000 claims 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims 1
- 239000004472 Lysine Substances 0.000 claims 1
- 206010060875 Uraemic pruritus Diseases 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 230000032683 aging Effects 0.000 claims 1
- 235000018417 cysteine Nutrition 0.000 claims 1
- 230000002950 deficient Effects 0.000 claims 1
- 239000007857 degradation product Substances 0.000 claims 1
- 108010084643 filaggrin Proteins 0.000 claims 1
- 230000000269 nucleophilic Effects 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 239000011780 sodium chloride Substances 0.000 claims 1
- 159000000000 sodium salts Chemical class 0.000 claims 1
Claims (13)
- 対象の尿素によって引き起こされるかゆみを伴う乾燥した皮膚の治療または予防に使用するための、求核剤を含む局所製剤。
- 前記求核剤が、ヒスチジン、ペプチド、およびそれらの誘導体のうちの少なくともいずれかのような求核アミノ酸である、請求項1に記載の局所製剤。
- 尿素によって引き起こされるかゆみを伴う乾燥した皮膚は、尿毒症性掻痒症、ウロストミー性皮膚炎、失禁性皮膚炎およびおむつ性皮膚炎からなる群より選択される、請求項1または2に記載の局所製剤。
- 前記局所製剤は、皮膚表面cm2当たり0.001mg〜5mgの範囲である求核剤の濃度にて皮膚に適用される、請求項1〜3のいずれか一項に記載の局所製剤。
- 前記誘導体は、ヒスチジン分解生成物、ヒスチジンのペプチド、ヒスチジンおよび1つ以上のさらなるアミノ酸のペプチド、ヒスチジンの薬学的に許容される塩の1つ以上から選択される、請求項2〜4のいずれか一項に記載の局所製剤。
- ヒスチジンはL−ヒスチジンである、請求項2〜5のいずれか一項に記載の局所製剤。
- ヒスチジンおよびその誘導体のいずれか一方は、前記局所製剤中における唯一の活性成分である、請求項2〜6のいずれか一項に記載の局所製剤。
- 前記局所製剤は、ピロリドンカルボン酸のナトリウム塩のようなピロリドンカルボン酸、またはグリシルグリシン、システイン、アルギニンおよびリジンからなる群より選択される1つ以上のアミノ酸、をさらに含む、請求項1〜6のいずれか一項に記載の局所製剤。
- 前記局所製剤は、ヒスチジンおよびその誘導体の少なくとも一方を、皮膚表面cm2当たり0.5mg〜2.5mgの範囲にある濃度にて皮膚に適用される、請求項1〜8のいずれか一項に記載の局所製剤。
- 前記求核剤はヒスチジンおよびその誘導体の両方またはいずれか一方である、請求項1に記載の局所製剤。
- 前記局所製剤は、ピロリドンカルボン酸をさらに含む、請求項10に記載の局所製剤。
- 高齢者の皮膚の老化における掻痒症の治療または予防における使用のための、請求項1〜9のいずれか一項に記載の局所製剤。
- フィラグリン欠損患者におけるかゆみを伴う乾燥した皮膚の治療または予防における使用のための、請求項1〜9のいずれか一項に記載の局所製剤。
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2022014925A JP7220316B2 (ja) | 2016-06-17 | 2022-02-02 | 尿毒症性掻痒症の治療に使用するための製剤 |
JP2022173435A JP2022187022A (ja) | 2016-06-17 | 2022-10-28 | 尿毒症性掻痒症の治療に使用するための製剤 |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DKPA201670438 | 2016-06-17 | ||
DKPA201670438 | 2016-06-17 | ||
DKPA201770225 | 2017-03-28 | ||
DKPA201770225 | 2017-03-28 | ||
PCT/DK2017/050201 WO2017215723A1 (en) | 2016-06-17 | 2017-06-16 | Formulation for use in the treatment of uremic pruritus |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2022014925A Division JP7220316B2 (ja) | 2016-06-17 | 2022-02-02 | 尿毒症性掻痒症の治療に使用するための製剤 |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2019518084A JP2019518084A (ja) | 2019-06-27 |
JP2019518084A5 true JP2019518084A5 (ja) | 2020-07-27 |
JP7019684B2 JP7019684B2 (ja) | 2022-02-15 |
Family
ID=60663348
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2019518350A Active JP7019684B2 (ja) | 2016-06-17 | 2017-06-16 | 尿毒症性掻痒症の治療に使用するための製剤 |
JP2022014925A Active JP7220316B2 (ja) | 2016-06-17 | 2022-02-02 | 尿毒症性掻痒症の治療に使用するための製剤 |
JP2022173435A Pending JP2022187022A (ja) | 2016-06-17 | 2022-10-28 | 尿毒症性掻痒症の治療に使用するための製剤 |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2022014925A Active JP7220316B2 (ja) | 2016-06-17 | 2022-02-02 | 尿毒症性掻痒症の治療に使用するための製剤 |
JP2022173435A Pending JP2022187022A (ja) | 2016-06-17 | 2022-10-28 | 尿毒症性掻痒症の治療に使用するための製剤 |
Country Status (10)
Country | Link |
---|---|
US (2) | US10806721B2 (ja) |
EP (2) | EP3471720A4 (ja) |
JP (3) | JP7019684B2 (ja) |
KR (3) | KR20220143149A (ja) |
CN (2) | CN109414430B (ja) |
AU (2) | AU2017283511B2 (ja) |
BR (1) | BR112018076229A2 (ja) |
CA (1) | CA3026620C (ja) |
RU (1) | RU2018146294A (ja) |
WO (1) | WO2017215723A1 (ja) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2017283511B2 (en) * | 2016-06-17 | 2020-02-06 | Drug Delivery Solutions Aps | Formulation for use in the treatment of uremic pruritus |
WO2023194400A1 (en) * | 2022-04-06 | 2023-10-12 | Mc2 Therapeutics Ltd | Topical formulation for use in the treatment or prevention of itchy dry skin |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4025645A (en) | 1976-01-27 | 1977-05-24 | Jelenko Iii Carl | Non-steroid topical agent for alleviating inflammation in mammals |
US5811446A (en) | 1997-04-18 | 1998-09-22 | Cytos Pharmaceuticals Llc | Prophylactic and therapeutic methods for ocular degenerative diseases and inflammations and histidine compositions therefor |
US6573302B1 (en) * | 1999-09-29 | 2003-06-03 | Medical Merchandising, Inc. | Cream utilizing capsaicin |
US20060211754A1 (en) | 2005-03-16 | 2006-09-21 | Yu Ruey J | Compositions comprising N-propanoyl derivatives of amino acids, aminocarbohydrates and derivatives thereof |
US20070065396A1 (en) | 2005-09-21 | 2007-03-22 | Tracie Martyn International, Llc | Topical macqui berry formulation |
JP5168996B2 (ja) * | 2007-04-13 | 2013-03-27 | 味の素株式会社 | アミノ酸類高配合防腐水溶液 |
FR2916351B1 (fr) | 2007-05-22 | 2012-12-07 | Galderma Res & Dev | Composition pharmaceutique comprenant au moins deux composes choisis parmi l'acide pyrrolidone-5-carboxylique, la citrulline, l'arginine et l'asparagine et leur utilisation dans le traitement de la dermatite atopique |
US20090017129A1 (en) | 2007-07-13 | 2009-01-15 | Ma Or Ze Ev | Dead Sea minerals enriched anti-inflammatory pharmaceutical composition for treatment of cutaneous dryness, itching, peeling and tightness, especially in hemodialysis patients and preparation and treatment methods thereof |
US8337820B2 (en) | 2008-02-13 | 2012-12-25 | Bart Nieuwenhuijsen | Composition of a water-soluble sunscreen preparation for acne rosacea |
GB0803054D0 (en) | 2008-02-20 | 2008-03-26 | Univ Manchester | Medicament |
CN102171149B (zh) | 2008-07-23 | 2014-07-23 | F·恩斯 | 生产苏打化学品的组合固体废物、二氧化碳生石灰喷射、盐水和反渗透/离子交换法 |
FR2938193B1 (fr) * | 2008-11-07 | 2011-08-12 | Expanscience Lab | Medicament ou composition dermatologique comprenant un extrait peptidique d'avocat destine au traitement et a la prevention du prupit |
MX2011006821A (es) | 2008-12-26 | 2012-01-03 | Glenmark Pharmaceuticals Sa | Derivados de imidazol fusionados como antagonistas de trpv3. |
DE102011110909A1 (de) * | 2011-08-18 | 2013-02-21 | Paul Hartmann Ag | Zusammensetzungen mit einer die Hautbarriere verbessernden Wirkstoffkombination |
EP2869897A4 (en) | 2012-07-06 | 2016-09-28 | Univ Duke | ACTIVATION OF THE TRPV4 ION CHANNEL BY PHYSICAL STIMULI AND IMPORTANT ROLE FOR TRPV4 IN ORGANIC INFLAMMATION AND JUCKREIZ |
US20160008297A1 (en) | 2012-08-23 | 2016-01-14 | B.R.A.I.N. Biotechnology Research And Information Network Ag | Compounds for preventing, reducing and/or alleviating itchy skin condition(s) |
CN103908467B (zh) * | 2013-01-05 | 2017-02-08 | 西藏博睿生物科技有限公司 | 一种药物组合物及制剂 |
AU2017283511B2 (en) * | 2016-06-17 | 2020-02-06 | Drug Delivery Solutions Aps | Formulation for use in the treatment of uremic pruritus |
-
2017
- 2017-06-16 AU AU2017283511A patent/AU2017283511B2/en active Active
- 2017-06-16 KR KR1020227035218A patent/KR20220143149A/ko not_active IP Right Cessation
- 2017-06-16 US US16/310,025 patent/US10806721B2/en active Active
- 2017-06-16 CN CN201780042643.4A patent/CN109414430B/zh active Active
- 2017-06-16 KR KR1020197000483A patent/KR102454777B1/ko active IP Right Grant
- 2017-06-16 CN CN202211256647.1A patent/CN115671098A/zh active Pending
- 2017-06-16 KR KR1020247020977A patent/KR20240100484A/ko unknown
- 2017-06-16 BR BR112018076229-6A patent/BR112018076229A2/pt not_active Application Discontinuation
- 2017-06-16 RU RU2018146294A patent/RU2018146294A/ru unknown
- 2017-06-16 EP EP17812796.5A patent/EP3471720A4/en active Pending
- 2017-06-16 EP EP24178043.6A patent/EP4397368A2/en active Pending
- 2017-06-16 WO PCT/DK2017/050201 patent/WO2017215723A1/en active Application Filing
- 2017-06-16 JP JP2019518350A patent/JP7019684B2/ja active Active
- 2017-06-16 CA CA3026620A patent/CA3026620C/en active Active
-
2020
- 2020-04-27 AU AU2020202785A patent/AU2020202785B2/en active Active
- 2020-09-18 US US17/025,548 patent/US20210000796A1/en not_active Abandoned
-
2022
- 2022-02-02 JP JP2022014925A patent/JP7220316B2/ja active Active
- 2022-10-28 JP JP2022173435A patent/JP2022187022A/ja active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2925876T3 (es) | Nuevo tratamiento de las úlceras crónicas | |
HRP20200434T1 (hr) | Stabilne vodene formulacije adalimumaba | |
JP2012236857A5 (ja) | ||
MX2015004290A (es) | Formulacion que contiene virus y uso de la misma. | |
CA3030422C (en) | Stabilizing excipients for therapeutic protein formulations | |
JP2011529038A5 (ja) | ||
CO6210803A2 (es) | Formulaciones liquidas formadoras de pelicula dermica para la liberacion de farmaco a la piel | |
JP2012531448A5 (ja) | ||
MX2022012359A (es) | Formulacion. | |
JP2015512403A5 (ja) | ||
RU2014142038A (ru) | Короткие антимикробные липопептиды | |
JP2010536745A5 (ja) | ||
US20080299228A1 (en) | Topical compositions comprising a macromolecule and methods of using same | |
JP2019518084A5 (ja) | ||
MX354985B (es) | Conjunto de juguete de construcción. | |
WO2020170033A8 (en) | Method for treatment of moderate to severe erythema symptoms in rosacea patients | |
JP2016196419A (ja) | 皮膚外用製剤 | |
BR112015020443A8 (pt) | formulação em pó para inalação, seus usos e seu processo de preparação, e composição farmacêutica | |
RU2018146294A (ru) | Композиция для лечения уремического зуда | |
NZ719321A (en) | Storage stable lyophilized tripeptide formulations | |
MY191712A (en) | Composition comprising at least one dry powder obtained by spray drying to increase the stability of the formulation | |
WO2015100348A8 (en) | Keloid reduction using topical allantoin | |
MX2018013477A (es) | Acidos carboxilicos para tratar/prevenir una enfermedad de la piel. | |
US8092843B2 (en) | Method and composition for cutaneous treatment of herpes simplex infections | |
MX2018013474A (es) | Acidos carboxilicos para aplicacion en la primera infancia. |